Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(6):406-407; doi:10.1093/jnci/94.6.406
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gupta, R. A.
Right arrow Articles by DuBois, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, R. A.
Right arrow Articles by DuBois, R. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 6, 406-407, March 20, 2002
© 2002 Oxford University Press

EDITORIAL

Cyclooxygenase-2 Inhibitor Therapy for the Prevention of Esophageal Adenocarcinoma in Barrett's Esophagus

Rajnish A. Gupta, Raymond N. DuBois

Affiliations of authors: Departments of Medicine and Cell Biology, Vanderbilt University Medical Center and Department of Veterans Affairs Medical Center, Nashville, TN.

Correspondence to: Raymond N. DuBois, M.D., Ph.D., Dept. of Medicine/GI, MCN C-2104, Vanderbilt University Medical Center, 1161 21st Ave. South, Nashville, TN 37232–2279 (e-mail: raymond.dubois@mcmail.vanderbilt.edu).

The outcome for patients diagnosed with esophageal adenocarcinoma remains abysmal despite a better understanding of the molecular events that underlie development of the disease. Additionally, the incidence for this type of esophageal carcinoma has been rapidly increasing in the United States over the last three decades (1). Esophageal adenocarcinoma often occurs in the setting of Barrett's esophagus, a condition caused by chronic gastroesophageal reflux, which is characterized histologically by a transition of the squamous cell mucosa of the distal esophagus to metaplastic columnar epithelial cells (2). Patients with Barrett's esophagus are clearly at increased risk for developing esophageal . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
S. P Mehta, A. P Boddy, J. Cook, V. Sams, E. K Lund, I. T Johnson, and M. Rhodes
Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus
Am. J. Clinical Nutrition, April 1, 2008; 87(4): 949 - 956.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ferrario, A. M. Fisher, N. Rucker, and C. J. Gomer
Celecoxib and NS-398 Enhance Photodynamic Therapy by Increasing In vitro Apoptosis and Decreasing In vivo Inflammatory and Angiogenic Factors
Cancer Res., October 15, 2005; 65(20): 9473 - 9478.
[Abstract] [Full Text] [PDF]